Previous studies have indicated that inflammatory biomarkers such as CRP (42), MPO (33), TNF-α (9), MCP-1 (43), and VCAM-1 (10) can predict the risk of future CAD, plaque stability, and adverse clinical outcomes in CAD patients. This evidence concerns the gene CCL2 and coronary artery disorder.